NCT03128619View on ClinicalTrials.gov

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 2, 2017

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Estrogen Receptor PositiveHER2/Neu NegativeInvasive Breast CarcinomaMultifocal Breast CarcinomaPostmenopausalProgesterone Receptor PositiveStage I Breast CancerStage IA Breast CancerStage IB Breast CancerStage II Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage III Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
PROCEDURE

Biopsy of Breast

Undergo biopsy

DRUG

Copanlisib

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Letrozole

Given PO

DRUG

Palbociclib

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Translational Research in Oncology-U.S. Inc. (TRIO-US)

UNKNOWN

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT03128619 - Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer | Biotech Hunter | Biotech Hunter